European Journal of Clinical Investigation最新文献

{"title":"Why Circulating Interleukin-6 Is Not Yet a Standalone Clinically Actionable Biomarker in HFrEF: A Context-of-Use Review","authors":"Yongxin Ye,&nbsp;Martina Colombo,&nbsp;Jennifer Meessen,&nbsp;Benoit Tyl,&nbsp;Deborah Novelli,&nbsp;Negin Hajizadeh,&nbsp;Hans-Peter Brunner-La Rocca,&nbsp;Adriaan Voors,&nbsp;Sara Klas,&nbsp;Stephan Schwers,&nbsp;Bjarke Follin,&nbsp;Roberto Latini","doi":"10.1111/eci.70261","DOIUrl":"https://doi.org/10.1111/eci.70261","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Interleukin-6 (IL-6) is frequently measured in heart failure with reduced ejection fraction (HFrEF), but its clinical utility remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To assess IL-6 as a biomarker in HFrEF, with emphasis on the effect of treatments (pharmacodynamics) and translation readiness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>MEDLINE and EMBASE were searched through June 2026. Using AI-assisted full-text screening with manual adjudication, eligible studies were classified using BEST classification as prognostic, predictive and/or pharmacodynamic biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eighty studies met inclusion criteria (59 pharmacodynamic, 21 prognostic, 3 predictive; categories overlapping). Across prognostic studies, higher IL-6 consistently tracked disease severity and cardiovascular mortality risk, but associations with hospitalization and composite endpoints weakened after adjustment for natriuretic peptides, limiting incremental clinical value. Pharmacodynamic studies showed that several interventions reduce circulating IL-6—most consistently statins and levosimendan—while findings were heterogeneous for exercise, cardiac device, and sodium–glucose co-transporter-2 inhibitors. However, IL-6 changes did not consistently parallel clinical benefit, arguing against its use as a surrogate measure for outcome improvement. No study supported IL-6 as a predictive biomarker. Assay heterogeneity was substantial, with limited use of in vitro diagnosis-grade assays, representing a major barrier to qualification.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In HFrEF, IL-6 reflects inflammatory burden and may serve as pharmacodynamic readout in mechanistic studies, but it is not supported for treatment selection and adds limited prognostic information beyond natriuretic peptides. Progress towards translational utility requires standardized measurements and, potentially, biomarkers reflecting the IL-6 axis beyond IL-6 alone.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 10","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70261","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Failure Outcomes and Empagliflozin Treatment in Patients With Rheumatoid Arthritis: An EMPEROR-Pooled Analysis","authors":"João Pedro Ferreira,&nbsp;Faiez Zannad,&nbsp;Javed Butler,&nbsp;Francisco Vasques-Nóvoa,&nbsp;Pedro Marques,&nbsp;Betânia Ferreira,&nbsp;Milton Packer","doi":"10.1111/eci.70264","DOIUrl":"10.1111/eci.70264","url":null,"abstract":"","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 10","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Clinical measures in chronic neuropathic pain are related to the Kennedy and endocannabinoid pathway’","authors":"","doi":"10.1111/eci.70265","DOIUrl":"10.1111/eci.70265","url":null,"abstract":"<p>\u0000 <span>Bourke, S. L.</span>, <span>E. G. Suarez</span>, <span>B. Islam</span>, <span>J. Stephenson</span>, <span>D. P. Finn</span>, and <span>P. C. McHugh</span>. <span>2025</span>. “ <span>Clinical Measures in Chronic Neuropathic Pain are Related to the Kennedy and Endocannabinoid Pathways</span>.” <i>European Journal of Clinical Investigation</i> <span>55</span>, no. <span>2</span>: e14351. https://doi.org/10.1002/eci.14351.\u0000 </p><p>In the original submission, it was stated that David P. Finn and Patrick C. McHugh are joint senior authors. This statement was inadvertently omitted during the proofing stage. The following statement should have been included:</p><p><b>David P. Finn and Patrick C. McHugh are joint senior authors</b>.</p><p>We apologize for this error.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 10","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70265","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delirium in Patients With Traumatic Brain Injury and Long-Term Cognitive Decline: A Global Federated Real World Data Analysis","authors":"Amirreza Sabahizadeh,&nbsp;Amir Askarinejad,&nbsp;Koohyar Ahmadzadeh,&nbsp;Seyed Reza Mirjalili,&nbsp;Khashayar Farshid,&nbsp;Leandra Serio,&nbsp;Enrico Tartaglia,&nbsp;Riccardo Proietti,&nbsp;Rhys Davies,&nbsp;Gregory Y. H. Lip","doi":"10.1111/eci.70262","DOIUrl":"10.1111/eci.70262","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objective</h3>\u0000 \u0000 <p>Delirium may occur in patients with traumatic brain injury (TBI), but this may be a marker for subsequent cognitive decline post-TBI. We aimed to compare cognitive outcomes and all-cause mortality between TBI patients with and without delirium.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study using the TriNetX global federated research network. We compared TBI patients who developed delirium within 14 days of TBI diagnosis with those who did not. The primary outcome was the 2-year composite risk of dementia, vascular dementia and Alzheimer's disease. Secondary outcomes included dementia, vascular dementia, Alzheimer's disease and all-cause mortality. Pre-specified subgroup analyses were performed in female patients, older adults (≥ 75 years), and individuals with substance use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TBI patients with delirium (<i>n</i> = 2564; mean age, 66.6 ± 19.4 years; 59.4% male), when compared with TBI patients without delirium (<i>n</i> = 667,950; mean age, 48.0 ± 25.1 years; 60.3% male), had more baseline comorbidities, including psychiatric disease, cerebrovascular disease and ischemic heart disease. After propensity score matching, TBI patients with delirium, compared with those without delirium, had a higher 2-year risk of the primary composite outcome (HR, 2.47; 95% CI, 1.84–3.31), as well as dementia (HR, 2.63; 95% CI, 1.92–3.60), vascular dementia (HR, 2.76; 95% CI, 1.45–5.24) and Alzheimer's disease (HR, 2.23; 95% CI, 1.21–4.09).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Delirium following TBI is associated with an increased risk of dementia and Alzheimer's disease. Delirium post-TBI may be a marker or a contributing factor to long-term cognitive decline in TBI patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 10","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13633596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proprotein Convertase Subtilisin/Kexin Type 9: From Biology to Therapeutic Targeting in Cardiovascular Disease.","authors":"Riccardo Rizzo, Bianca S Daraban, Irina F Tudorache, Davide Barbarossa, Francesca Protopapa, Amirbahman Zeynali, Francesco M Esposito, Alberico L Catapano","doi":"10.1111/eci.70263","DOIUrl":"https://doi.org/10.1111/eci.70263","url":null,"abstract":"<p><strong>Background: </strong>Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a pivotal regulator of cholesterol homeostasis, primarily known for inducing the degradation of the low-density lipoprotein receptor (LDLR). Beyond this classical pathway, PCSK9 exerts complex pleiotropic effects and interacts with various lipoproteins, contributing to cardiovascular and metabolic pathologies. This review synthesizes current knowledge on PCSK9 biology, its multi-organ implications and evolving therapeutic strategies.</p><p><strong>Methods: </strong>This narrative review summarizes current evidence from experimental, translational and clinical studies on PCSK9 biology and therapeutics. The literature examined includes studies on PCSK9 transcriptional regulation, post-translational modifications, interactions with lipoproteins and the clinical development of established and emerging PCSK9-targeting therapies.</p><p><strong>Results: </strong>PCSK9 activity is modulated by several transcription factors (e.g., SREBP2, HNF1α) and post-translational processes such as furin cleavage and sulfation. Clinically, elevated PCSK9 levels are linked to atherosclerosis progression, heart failure and adverse outcomes in infectious diseases and certain malignancies. Monoclonal antibodies (alirocumab, evolocumab) and siRNA (inclisiran) consistently reduce LDL-C by 50%-60%. Emerging approaches include oral inhibitors which may broaden access to PCSK9-targeting therapy, and CRISPR-based gene-editing strategies (e.g., VERVE-102), which aim to achieve sustained LDL-C lowering after a single treatment.</p><p><strong>Conclusions: </strong>PCSK9 is a multifaceted protein with roles extending far beyond LDL-C regulation. Understanding its diverse interactions is crucial for optimizing treatment in cardiovascular disease and potentially expanding its therapeutic application to metabolic and infectious conditions.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 10","pages":"e70263"},"PeriodicalIF":4.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies","authors":"Sasha Raman,&nbsp;Sreya Rahman,&nbsp;Francesca Polverino,&nbsp;Muhammad Adrish","doi":"10.1111/eci.70256","DOIUrl":"https://doi.org/10.1111/eci.70256","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disorder driven by neutrophilic and eosinophilic inflammation, structural changes, and airflow limitation. Shared pathophysiology makes cardiovascular disease a prevalent COPD comorbidity, necessitating an integrated cardiopulmonary assessment. Screening questionnaires may aid early COPD detection. CT imaging can supplement spirometry to characterise structural changes. Recent advances have shifted COPD management toward phenotype-directed approaches that incorporate novel biomarkers and emerging targeted therapies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This narrative review summarises recent advances in COPD management. Relevant literature was identified through database searches focusing on COPD guidelines, randomised controlled trials, systematic reviews, and emerging therapies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Current management emphasises smoking and e-cigarette cessation, vaccination against respiratory pathogens, and early recognition of disease phenotypes. Blood eosinophils and other biomarkers correlate with corticosteroid responsiveness. Dual long-acting bronchodilator therapy (LABA/LAMA) remains foundational for maintenance treatment, while triple therapy (ICS/LABA/LAMA) reduces exacerbations in patients with recurrent exacerbations and eosinophilic inflammation. Advances in targeted therapies include biologics such as dupilumab and mepolizumab that improve outcomes in patients with eosinophilic COPD. Phosphodiesterase inhibitors provide additional therapeutic options including ensifentrine, which combines bronchodilator and anti-inflammatory effects, and roflumilast, which reduces frequent exacerbations and chronic bronchitis. Emerging therapies that target inflammatory pathways including tezepelumab, and IL-33 inhibitors such as astegolimab, itepekimab, and tozorakimab, are under investigation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>COPD management is evolving toward precision medicine, guided by inflammatory phenotypes, biomarkers, and individualised risk profiles. Continued investigation into targeted biologics, anti-inflammatory agents, and incorporating biomarkers into clinical practice may improve outcomes and reduce disease burden.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 10","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70256","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149014745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Invasive Assessment of Endothelial Dysfunction and Arterial Stiffness in Fontan Circulation","authors":"Amalia Baroutidou,&nbsp;Eleni Pagkopoulou,&nbsp;Vasileios Kamperidis,&nbsp;Antonios Ziakas,&nbsp;Theodoros Dimitroulas,&nbsp;George Giannakoulas","doi":"10.1111/eci.70257","DOIUrl":"10.1111/eci.70257","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Fontan procedure constitutes the definitive surgical strategy for complex congenital heart disease, establishing a circulation in which systemic venous blood is directed to the pulmonary arteries through a staged reconstruction that separates systemic and pulmonary venous return in the absence of a subpulmonary ventricle. This uniquely altered haemodynamic state exerts deleterious effects on endothelial function, thereby promoting progressive end-organ dysfunction and contributing substantially to the long-term morbidity observed in patients with Fontan circulation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Μethods/Results</h3>\u0000 \u0000 <p>Over recent decades, clinical research has employed a range of functional methods to assess macro- and microvascular function, as well as arterial stiffness. This review summarizes the available functional non-invasive techniques for evaluating vascular function in the Fontan circulation and discusses the existing evidence linking these vascular parameters to cardiac dysfunction, associated comorbidities, and clinical outcomes in this population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Functional non-invasive vascular assessment may provide valuable information for monitoring disease progression and risk stratification in Fontan circulation; however, further longitudinal studies are required to clarify its prognostic significance and potential clinical utility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 9","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13577340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Cancer Across Cardiovascular and Cardiometabolic Conditions: A Systematic Review and Meta-Analysis","authors":"Akhmetzhan Galimzhanov,&nbsp;Elif Beytekin,&nbsp;Leh Chuan Lim,&nbsp;Abdul Basit Ali Zai,&nbsp;Gemina Doolub,&nbsp;Mustafa Aljarshawi,&nbsp;Balamrit Singh Sokhal,&nbsp;Andrija Matetic,&nbsp;Rodrigo Bagur,&nbsp;Louise Y. Sun,&nbsp;Cheng Han Ng,&nbsp;Miguel Nobre Menezes,&nbsp;Sarah Zaman,&nbsp;Bonnie Ky,&nbsp;Mamas A. Mamas","doi":"10.1111/eci.70260","DOIUrl":"10.1111/eci.70260","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To the best of our knowledge, no previous systematic review has comprehensively quantified cancer prevalence across the broad spectrum of cardiovascular and cardiometabolic conditions included in the present study. We aimed to estimate pooled prevalence of active cancer (primary outcome) and other cancer categories among patients with coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), hypertension, Type 2 diabetes mellitus (DM), stroke, peripheral artery disease (PAD), and valvular heart disease (VHD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, Web of Science, and Scopus were searched from 2010 to July 2024. Secondary outcomes included prevalence of any, previous, haematological, solid, and metastatic cancer. Prevalence estimates were calculated using one-step generalized linear mixed models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 676 studies comprising approximately 180 million participants were included. The primary analysis of active cancer included 59 studies (4,759,695 patients). Active cancer prevalence ranged from 4.22% (95% confidence interval [CI] 2.18–5.32) in Type 2 DM to 5.55% (95% CI 3.97–7.01) in AF. The prevalence of any cancer, a secondary outcome with more heterogeneous ascertainment, ranged from 7.04% (95% CI 6.05–8.03) in CAD to 14.10% (95% CI 12.20–15.99) in AF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Cancer represents a substantial comorbidity across cardiovascular and cardiometabolic conditions. Although cancer ascertainment methods varied across studies, particularly for any cancer, the findings provide contemporary estimates of cancer burden that may inform future cardio-oncology research, healthcare planning, risk stratification, and the design of cardiovascular and cardiometabolic clinical trials.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>PROSPERO CRD42023494764</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 9","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Murine ADAM15 Deficiency Is Associated With Atrial Remodelling and Atrial Arrhythmia Susceptibility","authors":"Aneesh Bapat,&nbsp;Sebastian Clauss,&nbsp;Ling Xiao,&nbsp;Heather Jameson,&nbsp;Anthony Retournard,&nbsp;Alan Hanley,&nbsp;Patrick T. Ellinor","doi":"10.1111/eci.70259","DOIUrl":"10.1111/eci.70259","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with significant associated morbidity and mortality. The pathophysiology underlying AF is complex, and this has limited the development of effective therapies. ADAMs (a disintegrin and metalloproteinase) are transmembrane proteinases with diverse functions involving cell–cell communication and extracellular matrix homeostasis. ADAM15 specifically has been implicated in AF pathogenesis in large-scale genetic association studies. Given the importance of atrial remodelling in AF pathogenesis, we sought to ascertain the effect of ADAM15 deficiency in murine atrial biology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed extensive cardiac phenotyping in <i>Adam15</i> knockout (<i>Adam15</i>^−/−) mice; wildtype mice were used as controls. These studies included invasive electrophysiology, echocardiography, optical mapping and biochemical assays.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ADAM15 deficiency resulted in increased AF susceptibility without overt abnormalities in cardiac structure or function by echocardiography. These findings were associated with shortened atrial action potential duration, increased atrial fibrosis, increased TGFβ signalling, as well as reduced connexin expression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Here, we provide evidence that ADAM15 deficiency is associated with increased AF susceptibility and atrial remodelling in mice. Further work will be needed to define the molecular mechanisms underlying these findings and determine their relevance to human AF.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 9","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Andes Virus: From Transmission Dynamics to Pandemic Potential","authors":"Matteo Bassetti,&nbsp;Chiara Sepulcri,&nbsp;Luca Maria Bucci,&nbsp;Daniele Roberto Giacobbe,&nbsp;Antonio Vena","doi":"10.1111/eci.70255","DOIUrl":"10.1111/eci.70255","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Andes virus (ANDV) has recently emerged as a significant public health concern following a multi-country outbreak aboard the MV Hondius cruise ship in April 2026, with 13 identified cases and three deaths among passengers and crew.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We reviewed available literature from PubMed and Google Scholar databases and searched international health agencies, including the World Health Organisation and national public health authorities, for current outbreak information and up-to-date epidemiological data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ANDV is a zoonotic orthohantavirus endemic in southern Chile and Argentina, with <i>Oligoryzomys longicaudatus</i> as its principal reservoir. Approximately 300 cases of hantavirus cardiopulmonary syndrome occur annually in the Americas. The virus causes severe disease through endothelial dysfunction and vascular leakage, resulting in rapidly progressive pulmonary edema and shock. Human-to-human transmission is characteristic of ANDV and occurs through respiratory and salivary routes during prolonged close contact. Clinical presentation includes nonspecific prodromal symptoms followed by rapid cardiopulmonary deterioration. Diagnosis relies on serological assays and RT-qPCR. Management is predominantly supportive, emphasising hemodynamic monitoring and early consideration of extracorporeal membrane oxygenation in severe cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite ANDV's severity and high mortality, its epidemic potential seems to be low. However, the recent outbreak underscores the importance of international surveillance coordination and rapid diagnostic capabilities for emerging zoonotic infections.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"56 9","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}